- Home
- ADVM vs XTKG Comparison
ADVM vs XTKG Comparison
Compare ADVM & XTKG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- XTKG
- Stock Information
- Founded
- ADVM 2006
- XTKG 1997
- Country
- ADVM United States
- XTKG Singapore
- Employees
- ADVM N/A
- XTKG N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- XTKG
- Sector
- ADVM Health Care
- XTKG
- Exchange
- ADVM Nasdaq
- XTKG NYSE
- Market Cap
- ADVM 141.9M
- XTKG 154.2M
- IPO Year
- ADVM 2014
- XTKG 2019
- Fundamental
- Price
- ADVM $6.76
- XTKG $0.20
- Analyst Decision
- ADVM Strong Buy
- XTKG
- Analyst Count
- ADVM 6
- XTKG 0
- Target Price
- ADVM $28.17
- XTKG N/A
- AVG Volume (30 Days)
- ADVM 163.1K
- XTKG 255.8K
- Earning Date
- ADVM 08-12-2024
- XTKG 09-17-2024
- Dividend Yield
- ADVM N/A
- XTKG N/A
- EPS Growth
- ADVM N/A
- XTKG N/A
- EPS
- ADVM N/A
- XTKG N/A
- Revenue
- ADVM N/A
- XTKG $16,824,823.00
- Revenue This Year
- ADVM N/A
- XTKG N/A
- Revenue Next Year
- ADVM $5,848.83
- XTKG N/A
- P/E Ratio
- ADVM N/A
- XTKG N/A
- Revenue Growth
- ADVM N/A
- XTKG 60.50
- 52 Week Low
- ADVM $6.38
- XTKG $0.19
- 52 Week High
- ADVM $29.70
- XTKG $2.64
- Technical
- Relative Strength Index (RSI)
- ADVM 43.95
- XTKG 17.77
- Support Level
- ADVM $6.64
- XTKG $0.27
- Resistance Level
- ADVM $7.00
- XTKG $0.31
- Average True Range (ATR)
- ADVM 0.40
- XTKG 0.04
- MACD
- ADVM -0.00
- XTKG -0.01
- Stochastic Oscillator
- ADVM 19.61
- XTKG 2.18
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries that operates across four business segments: digital technologies, renewable energy, Cryptomining Operations, and agriculture technologies.